Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER-2 Positive Breast Cancer × liposomal doxorubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 90 Breast Neoplasms 68 Fallopian Tube Neoplasms 36 Multiple Myeloma 26 Carcinoma, Ovarian Epithelial 24 Neoplasms 22 Triple Negative Breast Neoplasms 13 Lymphoma 13 Sarcoma 12 Neoplasm Metastasis 11 Lymphoma, Large B-Cell, Diffuse 9 Recurrence 8 Lymphoma, Non-Hodgkin 7 Hodgkin Disease 7 Prostatic Neoplasms 6 Pancreatic Neoplasms 5 Neoplasms, Plasma Cell 5 Burkitt Lymphoma 5 Solid Tumors 4 Sarcoma, Kaposi 4 Sarcoma, Ewing 4 Lymphoma, T-Cell, Peripheral 4 Carcinoma 4 Breast Neoplasms, Male 4 Uterine Cervical Neoplasms 3 Rhabdomyosarcoma 3 Osteosarcoma 3 Lymphoma, T-Cell 3 Lymphoma, Mantle-Cell 3 Lymphoma, Follicular 3

Interventions

Trastuzumab 2 liposomal doxorubicin 1 eribulin 1 Metformin 1 Doxorubicin 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02488564 2025-02-03

met-HEReMYTA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed

HER-2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡